{
    "clinical_study": {
        "@rank": "168114", 
        "brief_summary": {
            "textblock": "Determine the relapse-free survival of resected pancreatic cancer patients following two\n      novel regimens with activity in advanced disease."
        }, 
        "brief_title": "A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pancreatic Adenocarcinoma", 
        "condition_browse": {
            "mesh_term": "Adenocarcinoma"
        }, 
        "detailed_description": {
            "textblock": "The objective of this study are to determine the relapse-free survival of resected\n      pancreatic cancer patients following two novel regimens.  The secondary objectives are 1) to\n      assess the toxicity of each of these regimens in this setting. 2) To perform exploratory\n      genomic analyses as a means of assessing molecular characteristics potentially associated\n      with risk of relapse with one or both of the regimens. 3) To determine the relationship\n      between known mutations and metabolic activity as measured by FDG-PET and risk of relapse."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have histologically or cytologically confirmed evidence of pancreatic\n             carcinoma.\n\n          -  Patients must have had all gross disease resected (R0 or R1 resection).\n\n          -  Patients who underwent an R2 resection are not eligible.\n\n          -  Patients must have had no prior chemotherapy or radiation therapy for pancreatic\n             cancer.\n\n          -  Age > 18 years.\n\n          -  Patient must have ECOG performance status of 0-2.\n\n          -  Patients must have normal organ and marrow function measured within 2 weeks. prior to\n             registration as follows:\n\n        ANC > 1,500/\u00b5L Platelets > 100,000/\u00b5L Total bilirubim less than 2-fold ULN\n        AST(SGOT)/ALT(SGPT)<2.5X institutional upper limit of normal Creatinine clearance >\n        60mL/min for patients with creatinine levels above institutional normal.\n\n          -  Patients must be > 4 weeks and < 12 weeks post-surgery at time of study registration.\n\n          -  Women of childbearing potential and sexually active males are stronglt advised to use\n             appropriate contraceptive measures.\n\n        Women must not be pregnant or breast-feeding.  All agents used in this study as well as\n        radiation therapy to the abdomen have the potential for teratogenic or abortifacient\n        effects.  All females of childbearing potential must have a blood test or urine study\n        within 2 weeks prior to registration to rule out pregnancy.\n\n          -  Patients must not be receiving any other investigational agents.\n\n          -  Patients with known metastases are not eligible.\n\n          -  Patients with wounds that have not fully healed are not eligible.\n\n        Exclusion Criteria:\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01839799", 
            "org_study_id": "UPCC 03213"
        }, 
        "intervention": {
            "intervention_name": "Chemotherapy", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Patients", 
            "with", 
            "resected"
        ], 
        "lastchanged_date": "April 24, 2013", 
        "location": {
            "contact": {
                "email": "PennCancerTrials@emergingmed.com", 
                "last_name": "Peter O'Dwyer, MD", 
                "phone": "855-216-0098"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "Abramson Cancer Center of the University of Pennsylvania"
            }, 
            "investigator": {
                "last_name": "Peter O'Dwyer, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma", 
        "overall_contact": {
            "email": "PennCancerTrials@emergingmed.com", 
            "last_name": "Peter O'Dwyer, MD", 
            "phone": "855-216-0098"
        }, 
        "overall_official": {
            "affiliation": "Abramson Cancer Center of the University of Pennsylvania", 
            "last_name": "Peter O'Dwyer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01839799"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Abramson Cancer Center of the University of Pennsylvania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abramson Cancer Center of the University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}